

Douglas J Jolly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3041391/publications.pdf>

Version: 2024-02-01

29
papers

863
citations

687363

13
h-index

752698

20
g-index

29
all docs

29
docs citations

29
times ranked

922
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.4	158
2	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	1.2	135
3	Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression. <i>Molecular Therapy</i> , 2012, 20, 1689-1698.	8.2	119
4	Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. <i>Neuro-Oncology</i> , 2012, 14, 145-159.	1.2	117
5	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. <i>Neuro-Oncology</i> , 2017, 19, 930-939.	1.2	65
6	Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. <i>Neuro-Oncology</i> , 2017, 19, 918-929.	1.2	41
7	Evaluation of PCR and ELISA Assays for Screening Clinical Trial Subjects for Replication-Competent Retrovirus. <i>Human Gene Therapy</i> , 1997, 8, 1231-1241.	2.7	37
8	Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types. <i>Human Gene Therapy Methods</i> , 2016, 27, 17-31.	2.1	32
9	A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models. <i>Molecular Therapy - Oncolytics</i> , 2018, 8, 14-26.	4.4	26
10	Blockade of Type I Interferon (IFN) Production by Retroviral Replicating Vectors and Reduced Tumor Cell Responses to IFN Likely Contribute To Tumor Selectivity. <i>Journal of Virology</i> , 2014, 88, 10066-10077.	3.4	20
11	Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients. <i>Clinical Cancer Research</i> , 2018, 24, 4680-4693.	7.0	20
12	Retroviral Replicating Vectors in Cancer. <i>Methods in Enzymology</i> , 2012, 507, 199-228.	1.0	19
13	Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. <i>Cancer Gene Therapy</i> , 2018, 25, 184-195.	4.6	14
14	Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6176-6186.	7.0	13
15	Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 221-232.	5.1	12
16	Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models. <i>Human Gene Therapy</i> , 2018, 29, 437-451.	2.7	11
17	Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1199-1214.	3.1	11
18	PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models. <i>Oncotarget</i> , 2019, 10, 2252-2269.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC.. Journal of Clinical Oncology, 2017, 35, e13504-e13504.	1.6	1
20	Immune modulation after Toca 511 and Toca FC treatment of colorectal cancer patients.. Journal of Clinical Oncology, 2020, 38, 186-186.	1.6	1
21	Adenoviral Vectors: History and Perspective. , 0, , 39-59.		1
22	Prodrug Activator Gene Therapy of Ovarian Cancer using a Retroviral Replicating Vector. Gynecologic Oncology, 2017, 147, 197.	1.4	0
23	Abstract B010: Antitumor cellular immune response elicited by Toca 511 and Toca FC therapy in preclinical and clinical studies. , 2018, , .		0
24	Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment. , 2018, , .		0
25	Toca 511 and Toca FC in patients with gastrointestinal tumors in the Toca 6 study.. Journal of Clinical Oncology, 2018, 36, TPS880-TPS880.	1.6	0
26	Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.. Journal of Clinical Oncology, 2018, 36, TPS2613-TPS2613.	1.6	0
27	Abstract CT067: A phase 1b study of Toca 511, a retroviral replicating vector, followed by Toca FC in patients with advanced cancer. , 2018, , .		0
28	Abstract A018: Effects of Toca 511 and Toca FC on tumor microenvironment and peripheral blood populations in patients with advanced malignancies. , 2019, , .		0
29	The Manufacture of Genetic Viral Vector Products. , 0, , 229-244.		0